Jean Francois Formela Sells 2,860 Shares of Korro Bio (NASDAQ:KRRO) Stock

Posted by Stanley Muller on Jun 3rd, 2026

Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) Director Jean Francois Formela sold 2,860 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $13.95, for a total transaction of $39,897.00. Following the transaction, the director owned 194,655 shares in the company, valued at approximately $2,715,437.25. This represents a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Korro Bio Trading Down 14.9%

Shares of NASDAQ:KRRO opened at $11.00 on Wednesday. Korro Bio, Inc. has a 1 year low of $5.20 and a 1 year high of $55.89. The business has a fifty day simple moving average of $12.37 and a 200 day simple moving average of $10.63. The firm has a market cap of $158.62 million, a price-to-earnings ratio of -0.94 and a beta of 3.00.

Korro Bio (NASDAQ:KRRO – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 117.86%. On average, sell-side analysts forecast that Korro Bio, Inc. will post -5.36 EPS for the current year.

Key Headlines Impacting Korro Bio

Here are the key news stories impacting Korro Bio this week:

Negative Sentiment: CEO Ram Aiyar sold 15,152 shares on May 29 at an average price of $12.98, reducing his ownership by 16.84%. The sale was disclosed as being tied to tax withholding on vested equity awards, but insider selling can still weigh on sentiment. SEC filing
Negative Sentiment: Director Jean Francois Formela sold 2,860 shares on May 28 at $13.95, a transaction made under a pre-arranged 10b5-1 trading plan. While routine, the sale adds to the recent insider-selling overhang. SEC filing
Neutral Sentiment: Lifesci Capital initiated/updated coverage with a “Strong-Buy” rating and published earnings estimates that are slightly better than the broader consensus for FY2026 through FY2030, which supports the long-term outlook but does not offset near-term losses.
Negative Sentiment: The company’s most recent quarterly results missed EPS expectations, and Korro Bio continues to post sizable losses, reinforcing concerns about cash burn and profitability.

Analyst Ratings Changes

Several brokerages recently commented on KRRO. Lifesci Capital raised Korro Bio to a “strong-buy” rating in a research note on Friday, May 29th. JonesTrading upgraded shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Wall Street Zen raised shares of Korro Bio from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. HC Wainwright dropped their price target on shares of Korro Bio from $20.00 to $15.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Cantor Fitzgerald raised their price target on shares of Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Friday, March 13th. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Get Our Latest Stock Report on KRRO

Institutional Investors Weigh In On Korro Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in KRRO. Affinity Asset Advisors LLC bought a new stake in Korro Bio during the first quarter worth approximately $8,002,000. Nantahala Capital Management LLC bought a new position in shares of Korro Bio in the fourth quarter valued at approximately $4,806,000. ADAR1 Capital Management LLC acquired a new stake in shares of Korro Bio in the first quarter worth $6,113,000. TCG Crossover Management LLC acquired a new stake in shares of Korro Bio in the third quarter worth $19,937,000. Finally, Vanguard Group Inc. lifted its stake in shares of Korro Bio by 2.3% in the third quarter. Vanguard Group Inc. now owns 395,659 shares of the company’s stock worth $18,948,000 after buying an additional 8,921 shares during the last quarter. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio Company Profile

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.